Table 2. Therapeutic plasma exchange in clinically isolated syndrome and multiple sclerosis patients.
| CIS | RR-MS | SP-MS | PP-MS | All patients | |
|---|---|---|---|---|---|
| No. of patients | 21 | 46 | 18 | 5 | 90 |
| Time to TPE (days) a | 50 (2–145) | 60.5 (7–154) | 61.0 (18–163) | 99.0 (7–152) | 57.5 (2–163) |
| No. of TPE a | 6 (2–8) | 5 (3–8) | 5 (2–8) | 5 (3–5) | 5 (2–8) |
| TPE until effect a | 5 (2–8) | 5 (2–8) | 5 (2–7) | 3 (3–5) | 5 (2–8) |
| Clinical response to TPE a | 17 (81%) | 38 (82.6%) | 7 (38.9%) | 3 (60.0%) | 65 (72.2%) |
| EDSS before TPE a | 3.0 (1.0–8.5) | 3.25 (1.0–6.5) | 7.0 (5.5–8.5) | 6.5 (3.0–7.5) | 3.75 (1.0–8.5) |
| EDSS after TPE a | 2.0 (0.0–8.0) | 2.5 (1.0–6.5) | 6.75 (5.5–8.5) | 6.0 (2.5–7.5) | 3.0 (0.0–8.5) |
| EDSS at follow-up a | 2.0 (0.0–7.5) | 3.25 (1.0–7.0) | 7.5 (4.5–8.5) | 6.0 (3.0–8.0) | 3.5 (0.0–8.5) |
CIS = clinically isolated syndrome, EDSS = expanded disability status scale, MS = multiple sclerosis, No. = number, PP-MS = primary progressive MS with acute worsening, RR-MS = relapsing-remitting MS, SP-MS = secondary progressive MS with superimposed relapse, TPE = therapeutic plasma exchange.
a Median (range).